Literature DB >> 27177826

Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.

Laureen C Colis1, Seth B Herzon2.   

Abstract

(-)-Lomaiviticin A (1) is a cytotoxic bacterial metabolite that induces double-strand breaks in DNA. Here we show that the cytotoxicity of (-)-lomaiviticin A (1) is synergistically potentiated in the presence of VE-821 (7), an inhibitor of ataxia telangiectasia and Rad3-related protein (ATR). While 0.5nM 1 or 10μM 7 alone are non-lethal to K562 cells, co-incubation of the two leads to high levels of cell kill (81% and 94% after 24 and 48h, respectively). Mechanistic data indicate that cells treated with 1 and 7 suffer extensive DNA double-strand breaks and apoptosis. These data suggest combinations of 1 and 7 may be a valuable chemotherapeutic strategy.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Chemotherapy; DNA; Lomaiviticin; Natural product; Synergism

Mesh:

Substances:

Year:  2016        PMID: 27177826      PMCID: PMC4899226          DOI: 10.1016/j.bmcl.2016.04.090

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  43 in total

1.  Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma.

Authors:  Xufeng Chen; Patty Wong; Eric H Radany; Jeremy M Stark; Corentin Laulier; Jeffrey Y C Wong
Journal:  Mol Cancer Res       Date:  2012-06-22       Impact factor: 5.852

Review 2.  The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.

Authors:  Joanne Smith; Lye Mun Tho; Naihan Xu; David A Gillespie
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

3.  Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.

Authors:  Michele Tavecchio; Joanne M Munck; Celine Cano; David R Newell; Nicola J Curtin
Journal:  Cancer Chemother Pharmacol       Date:  2011-06-01       Impact factor: 3.333

4.  Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

Authors:  J-H Lee; M L Choy; L Ngo; S S Foster; Paul A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

Review 5.  The diazofluorene antitumor antibiotics: structural elucidation, biosynthetic, synthetic, and chemical biological studies.

Authors:  Seth B Herzon; Christina M Woo
Journal:  Nat Prod Rep       Date:  2011-10-28       Impact factor: 13.423

6.  Comparison of MTT and ATP-based assays for the measurement of viable cell number.

Authors:  R D Petty; L A Sutherland; E M Hunter; I A Cree
Journal:  J Biolumin Chemilumin       Date:  1995 Jan-Feb

Review 7.  Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy.

Authors:  Thomas Helleday; Helen E Bryant; Niklas Schultz
Journal:  Cell Cycle       Date:  2005-09-12       Impact factor: 4.534

8.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

Authors:  V M Richon; S Emiliani; E Verdin; Y Webb; R Breslow; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

Review 9.  GammaH2AX and cancer.

Authors:  William M Bonner; Christophe E Redon; Jennifer S Dickey; Asako J Nakamura; Olga A Sedelnikova; Stéphanie Solier; Yves Pommier
Journal:  Nat Rev Cancer       Date:  2008-11-13       Impact factor: 60.716

Review 10.  The comet assay for DNA damage and repair: principles, applications, and limitations.

Authors:  Andrew R Collins
Journal:  Mol Biotechnol       Date:  2004-03       Impact factor: 2.860

View more
  2 in total

1.  The Mechanism of Action of (-)-Lomaiviticin A.

Authors:  Seth B Herzon
Journal:  Acc Chem Res       Date:  2017-09-28       Impact factor: 22.384

2.  Mechanism of Nucleophilic Activation of (-)-Lomaiviticin A.

Authors:  Mengzhao Xue; Seth B Herzon
Journal:  J Am Chem Soc       Date:  2016-11-28       Impact factor: 15.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.